Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNICORN: Short-course Pre-operative Targeted Treatments in Resectable Colorectal Cancer
NCT05845450Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan, durvalumab, panitumumab, botensilimab, balstilimab and 4 more in colorectal cancer (CRC) (13 cohorts), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Major Pathological Response Rate at 5 weeks. Started May 2023; status: recruiting.
02
Drugs
trastuzumab deruxtecandurvalumabpanitumumabbotensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05845450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845450.